Statutory Profit Doesnt Reflect How Good ADMA Biologics Earnings Are

ADMA Stock  USD 20.11  1.72  7.88%   
About 55% of ADMA Biologics' investor base is interested to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are impartial. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
  
r Sm59 BKQ6 HX cLy,,RiD-YkfVSKe I2ZUeO8glala0I5QLNKgLmcICxxDaDNg raiIPiR

Read at finance.yahoo.com
Yahoo News
  

ADMA Biologics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ADMA Biologics Fundamental Analysis

We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Equity

Return On Equity Comparative Analysis

ADMA Biologics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

ADMA Biologics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.

Peers

ADMA Biologics Related Equities

ANTXAN2 Therapeutics   21.90   
0%
100.0%
FATEFate Therapeutics   18.28   
0%
83.0%
IBIOIbio   11.79   
0%
53.0%
XFORX4 Pharmaceuticals   11.43   
0%
52.0%
TFFPTff Pharmaceuticals   9.68   
0%
44.0%
SANASana Biotechnology   9.02   
0%
41.0%
MCRBSeres Therapeutics   6.52   
0%
29.0%
INMBINmune Bio   3.27   
0%
14.0%
PLRXPliant Therapeutics   2.00   
0%
9.0%
PLXProtalix Biotherapeutics   1.78   
0%
8.0%
STOKStoke Therapeutics   1.68   
0%
7.0%
ANEBAnebulo Pharmaceuticals   0.70   
0%
3.0%
AKBAAkebia Ther   0.49   
0%
2.0%
BCRXBioCryst Pharmaceuticals   0.13   
0%
1.0%
CDTXCidara Therapeutics   0.05   
0%
1.0%
CRBUCaribou Biosciences   0.45   
2.0%
0%
ATRAAtara Biotherapeutics   0.65   
2.0%
0%
MDGLMadrigal Pharmaceuticals   0.98   
4.0%
0%
ACLXArcellx   1.12   
5.0%
0%
VXRTVaxart   1.64   
7.0%
0%
ETNB89bio   1.64   
7.0%
0%
RCUSArcus Biosciences   2.28   
10.0%
0%
TNXPTonix Pharmaceuticals   5.00   
22.0%
0%

Complementary Tools for ADMA Stock analysis

When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum